Eolas Therapeutics Regains Full Rights to First-in-Class OX1R Antagonist AZD4041 from AstraZeneca

AZD4041 is aHighly Selective Orexin-1 Receptor（OX1R）Antagonist, by Eolas and AstraZeneca at the National Institute on Drug Abuse (NIDA) with the support of joint development.

Data shows,AZD4041 Showed promising preclinical data in addictive behaviors, and has completed Phase I clinical trials. The press release noted that current preclinical and early clinical data support the drug's potential to become a first-in-class The Potential of Non-Opioid Drug Therapies, used for treatmentSubstance Use Disorder(Including opioid, stimulant, and alcohol use disorders)。

Eolas CEO Albert Man said, the company believes in the drugCan significantly improve treatment outcomes for patients with opioid dependence and other addictions.

According to the new agreement signed this time, Eolas will conduct clinical trials for the existing new drugs. (IND) The project application assumes full responsibility and, with the support of the NIDA UG3 cooperative agreement, will handle AZD4041.Advanced to Phase II Clinical Trial。